07:31 AM EDT, 07/24/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of AstraZeneca (AZN.L, AZN.ST) and Daiichi Sankyo's combination drug for HER2-positive metastatic breast cancer. AstraZeneca said Friday that Enhertu, in combination with pertuzumab, was recommended as the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. The endorsement is based on the results from the Destiny-Breast09 late-stage trial, where the combination therapy reduced the risk of disease progression or death by 44% compared with a combination of taxane, trastuzumab and pertuzumab.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.